CytoSorbents Announces Commencement of Shareholder Rights Warrant Offering

CytoSorbents Corporation (NASDAQ: CTSO) initiated a Rights Offering on December 9, 2024, as announced by the company in a press release. The Rights Offering is in line with the Company’s Registration Statement on Form S-3 (File No. 333-281062), along with the prospectus and the prospectus supplement, which were filed with the U.S. Securities and Exchange Commission (SEC) on the same day.

All eligible stockholders and certain warrantholders as of the Record Date, December 16, 2024, will receive copies of the prospectus and the related prospectus supplement via mail, with the option to access the documents through the SEC’s website or obtain them from the information agent, D.F. King & Co., Inc. Furthermore, the Company will be providing certain ancillary documents related to the Rights Offering through the SEC filing.

In conjunction with the Rights Offering, CytoSorbents Corporation has entered into a Dealer-Manager Agreement with Moody Capital Solutions, Inc., who will act as the dealer-manager for the offering. Detailed information about the Rights Offering, including the terms and conditions, can be found in the prospectus and the related prospectus supplement, while additional insights are available in the various exhibits accompanying the Current Report on Form 8-K.

This offering marks a significant opportunity for stockholders to participate in the Rights Offering, exercising their Subscription Rights for the opportunity to purchase Units at a specified Unit subscription price. The company emphasized that the information provided in the offering is subject to change and is not yet complete.

The press release also outlined that the Rights Offering is not an offer to sell or a solicitation to buy securities, and it shall not constitute any offering in jurisdictions where such actions would be deemed unlawful without proper registration or qualification. Interested parties are advised to refer to the prospectus and related documents for comprehensive details about the Rights Offering.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Cytosorbents’s 8K filing here.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.